Entering text into the input field will update the search result below

Finch Therapeutics brings on Roivant Sciences' Matthew Blischak as CEO

Apr. 25, 2023 5:08 PM ETFinch Therapeutics Group, Inc. (FNCH)By: Anuron Mitra, SA News Editor2 Comments
  • Finch Therapeutics (NASDAQ:FNCH) on Tuesday said it had appointed Matthew Blischak as CEO, effective May 16.
  • The company said current CEO Mark Smith will conclude his role as top boss effective May 15.
  • FNCH also announced the appointment of Lance Thibault as CFO.
  • FNCH said Marc Blaustein will conclude his role as chief operating officer and as the company's principal financial officer, effective May 15.
  • According to FNCH, Blischak has more than 20 years of intellectual property experience in the life sciences industry. He joins the company from Roivant Sciences (ROIV).

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.